New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
09:09 EDTAStudy shows major advantages of HER2 IQFISH pharmDx in breast cancer diagnostics
Dako, an Agilent Technologies company, announced positive findings in an independent French multicenter study on the performance of Dako's HER2 IQFISH pharmDx. The Toulouse, France, breast cancer group led by Magali Lacroix-Triki has published a peer-reviewed publication in the Journal of Histopathology that supports the use and performance of Dako's HER2 IQFISH pharmDx for HER2 gene amplification status assessment in breast cancer. Dako introduced the cutting- edge IQFISH hybridization buffer chemistry in 2012. The IQFISH buffer reduces test turnaround time from 17 hours to just 3.5 hours. As an aid in the treatment decision, HER2 IQFISH pharmDx can quantitatively determine HER2 gene amplification in the tumor. The French study found that Instant Quality, or IQ, FISH provides "excellent quality signals without any background staining, thus allowing excellent reading conditions." The study also points out "almost perfect agreement between IQFISH and FISH" and that IQFISH is a "safe, reliable and fast method that is easy to use in routine practice" with few reruns. The statement is significant in that the tissue came from five different laboratories using four different fixation methods. The study concludes that the highly concordant results and assay robustness support IQFISH as a useful alternative to FISH, allowing reliable assessment of HER2 status. It also finds that using this method enables pathologists to report the results to the oncologist within a day, meaning patients can begin cancer treatment sooner than ever.
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
11:01 EDTAAgilent partners with Weill Cornell Medical College for ALS research
Subscribe for More Information
August 17, 2015
17:48 EDTAAgilent says confident in delivering on margin expansion goals
On the company Q3 earnings conference call, Agilent said that it is confident in delivering on margin expansion goals. The company noted that it is committed to a 22% operating margin by 2017 and will continue its buybacks in Q4. The company sees a number of areas of strength including Pharma, Life Science, Research and Diagnostics. The company is seeing double-digit growth in Pharma and has no reason to believe it will slow down. Agilent sees "a lot " of reasons to be positive on outlook.
16:21 EDTAAgilent says some U.S. and state government large deals delayed into Q4
Agilent said in a slides presentation that some US and state government large deals delayed into Q4. Customers in industrial markets continue cautious stance in light of macro-economic conditions.
16:09 EDTAAgilent narrows FY15 EPS view to $1.68-$1.72 from $1.67- $1.73
Subscribe for More Information
16:07 EDTAAgilent sees Q4 EPS 45c-49c, consensus 50c
Sees Q4 revenue $1.03B-$1.05B, consensus $1.06B.
16:06 EDTAAgilent reports Q3 EPS 44c, consensus 41c
Subscribe for More Information
14:48 EDTANotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Agilent (A), consensus 41c... Urban Outfitters (URBN), consensus 49c... MasTec (MTZ), consensus 15c... Fabrinet (FN), consensus 39c.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use